MetaCap

Lifecore Biomedical (LFCR) vs Turn Therapeutics (TTRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Turn Therapeutics (TTRX) has outperformed Lifecore Biomedical (LFCR) over the past year, gaining 147.6% versus a loss of 16.4%. Turn Therapeutics is the larger company by market cap ($247.5 million vs $242.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LFCR-16.36%TTRX+147.55%
+390%+159%-73%
Nov 21, 20251 yearNov 20, 2026
LFCR-1.69%TTRX+8.66%
+109%+19%-71%
Oct 6, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LFCR versus TTRX key metrics
MetricLFCRTTRX
Share price$6.39$8.10
Market cap$242.22M$247.49M
1-day change+0.31%-6.31%
YTD return-21.88%+105.46%
1-year return-16.36%+147.55%
5-year return-26.30%—
EPS (TTM)$-1.27$-0.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$128.87M—
Revenue growth (YoY)+0.47%—
Net income (latest FY)$-38.72M$-3.19M
Gross margin31.27%—
Operating margin-13.38%—
Net margin-30.04%—
52-week high$8.98$16.45
52-week low$3.63$2.70
Distance from 52-week high-28.84%-50.79%
Analyst consensusholdstrong_buy
Avg. price target upside-1.72%+208.83%
Average volume414.71K119.32K
Shares outstanding37.91M30.57M
Employees3822
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TTRX has outperformed LFCR by 163.9 percentage points over the past year.

About Lifecore Biomedical

LFCR stock →

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.

Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees

About Turn Therapeutics

TTRX stock →

Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

LFCR vs TTRX FAQ

Which is bigger, Lifecore Biomedical or Turn Therapeutics?

Turn Therapeutics (TTRX) is larger, with a market capitalization of $247.49M compared with $242.22M for Lifecore Biomedical (LFCR).

Which stock has performed better over the past year, LFCR or TTRX?

TTRX returned +147.55% over the past 12 months, compared with -16.36% for LFCR (price return, excluding dividends). Past performance does not predict future results.

Are Lifecore Biomedical and Turn Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons